Wells Fargo & Company Raises Albemarle (NYSE:ALB) Price Target to $110.00

Albemarle (NYSE:ALBFree Report) had its target price increased by Wells Fargo & Company from $100.00 to $110.00 in a report published on Tuesday morning, Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the specialty chemicals company’s stock.

Several other brokerages have also commented on ALB. Piper Sandler cut their target price on Albemarle from $95.00 to $90.00 and set an underweight rating on the stock in a research report on Thursday, August 8th. Baird R W downgraded shares of Albemarle from a strong-buy rating to a hold rating in a research report on Monday, August 5th. KeyCorp dropped their target price on shares of Albemarle from $151.00 to $132.00 and set an overweight rating on the stock in a research report on Monday, August 5th. JPMorgan Chase & Co. cut their target price on shares of Albemarle from $115.00 to $78.00 and set a neutral rating on the stock in a research note on Monday, August 19th. Finally, Berenberg Bank downgraded shares of Albemarle from a buy rating to a hold rating and decreased their price target for the company from $160.00 to $83.00 in a research note on Wednesday, July 31st. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Hold and an average price target of $117.60.

Read Our Latest Report on ALB

Albemarle Trading Down 0.9 %

Shares of NYSE ALB opened at $102.02 on Tuesday. The firm has a 50 day moving average price of $88.03 and a two-hundred day moving average price of $104.16. The stock has a market cap of $11.99 billion, a P/E ratio of -21.57, a price-to-earnings-growth ratio of 13.81 and a beta of 1.54. Albemarle has a 52-week low of $71.97 and a 52-week high of $177.52. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.75 and a current ratio of 2.67.

Albemarle (NYSE:ALBGet Free Report) last released its quarterly earnings results on Wednesday, July 31st. The specialty chemicals company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.49). Albemarle had a negative net margin of 6.72% and a positive return on equity of 6.38%. The company had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $1.34 billion. During the same quarter last year, the firm posted $7.33 EPS. The company’s quarterly revenue was down 39.7% on a year-over-year basis. As a group, equities analysts forecast that Albemarle will post 0.46 EPS for the current year.

Albemarle Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, October 1st. Stockholders of record on Friday, September 13th were given a dividend of $0.405 per share. The ex-dividend date was Friday, September 13th. This is a positive change from Albemarle’s previous quarterly dividend of $0.40. This represents a $1.62 annualized dividend and a dividend yield of 1.59%. Albemarle’s dividend payout ratio (DPR) is currently -34.25%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. WFA Asset Management Corp purchased a new stake in Albemarle in the 1st quarter worth about $25,000. Quarry LP purchased a new position in shares of Albemarle in the fourth quarter valued at $33,000. First Financial Corp IN bought a new stake in shares of Albemarle during the 1st quarter valued at $32,000. First Community Trust NA bought a new position in Albemarle in the 2nd quarter worth about $25,000. Finally, CVA Family Office LLC grew its holdings in Albemarle by 610.0% during the 2nd quarter. CVA Family Office LLC now owns 284 shares of the specialty chemicals company’s stock valued at $27,000 after buying an additional 244 shares in the last quarter. 92.87% of the stock is currently owned by hedge funds and other institutional investors.

About Albemarle

(Get Free Report)

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.

Further Reading

Analyst Recommendations for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.